Author: DrugPatentWatch - Page 19 - DrugPatentWatch

Artificial Intelligence and Machine Learning in Drug Discovery and Development

A recent paper published in the journal “Intelligent Medicine” article discusses various aspects of using AI and machine learning in […]

A recent study explores the landscape of authorized generics in the United States pharmaceutical market. Authorized generics are brand-name drugs

A recent update from Foley & Lardner attorney Courtenay C. Brinckerhoff discusses trends in Inter Partes Review (IPR) and Post Grant

In a recent Insight article published by Global Competition Review, legal experts from Lowenstein Sandler LLP delve into the status

In the world of prescription drugs, brand-name manufacturers have employed various strategies to maintain revenue streams in the face of

A review article in the Journal of Pharmaceutical Sciences analyzes the trends in drug repurposing through the 505(b)(2) pathway, as

Here’s a summary of a new article that used DrugPatentWatch data: NIH Funding for Patents That Contribute to Market Exclusivity

While answering a question for a DrugPatentWatch user, the question arose of technologies the NIH has licensed. It turns out

In a recent article published by IAM Magazine, titled “Why Pharma Companies Should File Patents Later In The R&D Process,”